Abstract

Mid-Regional proadrenomedullin (MR-PROADM) may be a new marker of severity status of patient with systemic inflammatory response-pilot project

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call